Medifast, Inc. MED
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +13.76%
- 1 year
- +0.08%
- Open
- 12.24
- Prev close
- 12.26
- Mkt cap
- 135.87M
- Vol
- 231.89K
- Avg vol
- 143.63K
- EPS
- -3.70
- P/E
- 0.00
- Div yield
- 34.41%
More statistics
- Low
- 12.00
- High
- 12.48
- Forward P/E
- 56.17
- Beta
- 1.16
- Short ratio
- 7.68
- Inst. own
- 86.16%
- Dividend
- 6.60
- Ex-div date
- Sep 17, 2023
- 50-d avg
- 18.72
- 200-d avg
- 22.71
- 1y target
- 16.50
News
5 days ago seekingalpha.com
Medifast Is Running The Same Playbook, And I Have The Same Concerns
Medifast (MED) maintains a strong, cash-heavy balance sheet and trades near liquidation value, but its business model remains uninspiring amid GLP-1 disruption. Q3 2026 revenue declined 19.4% YoY to…
5 days ago zacks.com
Medifast Q3 Loss Narrower Than Expected as Coach Productivity Rises
MED tops Q3 earnings expectations as coach productivity jumps 54.1% and margins expand, despite declining revenues and a shrinking coach network.
6 days ago seekingalpha.com
Medifast, Inc. (MED) Q3 2026 Earnings Call Transcript
Medifast, Inc. (MED) Q3 2026 Earnings Call Transcript
6 days ago marketbeat.com
What Medifast (MED) Said on Its Q3 Earnings Call
Medifast NYSE: MED reported third-quarter 2026 revenue of $72 million, down 19.4% from a year earlier, as the company continued to face a sharp decline in its active earning coach base. Management…
6 days ago zacks.com
Medifast (MED) Reports Q3 Loss, Tops Revenue Estimates
Medifast (MED) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.21 per share a year ago.
6 days ago benzinga.com
Medifast Q3 2026 Earnings Call Transcript
Medifast (NYSE:MED) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
-
6 days ago benzinga.com
Medifast Lowers FY2026 GAAP EPS Guidance from $(1.75)-$(0.25) to $(2.05)-$(1.80) vs $(0.94) Est
Medifast (NYSE:MED) lowers FY2026 GAAP EPS guidance from $(1.75)-$(0.25) to $(2.05)-$(1.80) vs $(0.94) analyst estimate..
-
6 days ago benzinga.com
Medifast Sees FY2026 Adj EPS $(0.70)-$(0.45) vs $(0.94) Est; Raises FY2026 Sales Guidance from $270.000M-$300.000M to $280.000M-$300.000M vs $287.700M Est
Medifast (NYSE:MED) is looking for FY2026 Adj EPS of $(0.70)-$(0.45) vs $(0.94) analyst estimate. Raises FY2026 sales outlook from $270.000 million-$300.000 million to $280.000 million-$300.000…
-
6 days ago benzinga.com
Medifast Q3 Adj. EPS $(0.19) Beats $(0.35) Estimate, Sales $72.048M Beat $71.300M Estimate
Medifast (NYSE:MED) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.35) by 45.71 percent. This is a 9.52 percent increase over losses of $(0.21) per…
-
6 days ago benzinga.com
Medifast Sees Q4 GAAP EPS $0.00-$0.25 vs $(0.12) Est; Sees Sales $55.000M-$75.000M vs $64.100M Est
Medifast (NYSE:MED) is looking for Q4 GAAP EPS of $0.00-$0.25 vs $(0.12) analyst estimate. sees sales of $55.000 million-$75.000 million vs $64.100 million analyst estimate.
6 days ago businesswire.com
Medifast Announces Third Quarter 2026 Financial Results
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the metabolic health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy™, today reported results for…